KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palvella Therapeutics (PVLA) Assets (2016 - 2026)

Palvella Therapeutics has reported Assets over the past 10 years, most recently at $95.5 million for Q4 2022.

  • Quarterly Assets fell 37.82% to $95.5 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $95.5 million through Dec 2022, down 37.82% year-over-year, with the annual reading at $95.5 million for FY2022, 37.82% down from the prior year.
  • Assets was $95.5 million for Q4 2022 at Palvella Therapeutics, down from $99.2 million in the prior quarter.
  • Over five years, Assets peaked at $173.2 million in Q1 2018 and troughed at $95.5 million in Q4 2022.
  • The 5-year median for Assets is $130.9 million (2019), against an average of $132.2 million.
  • Year-over-year, Assets soared 179.98% in 2018 and then plummeted 39.6% in 2022.
  • A 5-year view of Assets shows it stood at $141.3 million in 2018, then fell by 0.17% to $141.1 million in 2019, then fell by 25.58% to $105.0 million in 2020, then skyrocketed by 46.23% to $153.6 million in 2021, then plummeted by 37.82% to $95.5 million in 2022.
  • Per Business Quant, the three most recent readings for PVLA's Assets are $95.5 million (Q4 2022), $99.2 million (Q3 2022), and $114.3 million (Q2 2022).